Articles Referencing XOMA
Positive Data on Celgene's Apremilast - Analyst Blog
5/9/2013, 4:23 pm from Zacks.com in Investing, Business, Stocks
Celgene Corporation ( CELG ) recently
announced positive results from the PALACE 4 study on apremilast.
The study is evaluating apremilast (20 mg and 30 mg), a novel, oral
small-molecule... Read >>
Bayer Earnings Rise Y/Y - Analyst Blog
4/26/2013, 4:21 pm from Zacks.com in Investing, Business, Earnings, Stocks
Bayer 's ( BAYRY ) earnings
during the first quarter of 2013 came in at €1.70 per share
(approx. $2.24) compared with €1.67 per share (approx. $2.19) in
the year-ago period. Earnings... Read >>
AstraZeneca Earnings Tumble Y/Y - Analyst Blog
4/26/2013, 1:03 pm from Zacks.com in Investing, Business, Earnings, Stocks
AstraZeneca 's ( AZN ) first-quarter
2013 core earnings of $1.41 per American Depositary Share (ADS)
beat the Zacks Consensus Estimate of $1.34. Earnings were down 21%
(at constant... Read >>
AZN/BIND Therapeutics Ink Deal - Analyst Blog
4/23/2013, 7:11 pm from Zacks.com in Investing, Business, Stocks
AstraZeneca ( AZN ) recently
announced that it has entered into an agreement with BIND
Therapeutics for the development and commercialization of Accurin
(a cancer nanomedicine).
As per... Read >>
Illumina Beats on Earnings, Revenue - Analyst Blog
4/23/2013, 3:11 pm from Zacks.com in Investing, Business, Earnings, Stocks
Illumina Inc.'s ( ILMN ) first-quarter
2013 adjusted earnings of 46 cents per share beat the Zacks
Consensus Estimate by 21%. Adjusted earnings grew almost 28% over
the prior-year quarter... Read >>
AZN Inks Biomarker Discovery Deal - Analyst Blog
4/18/2013, 7:10 pm from Zacks.com in Investing, Business, Stocks
AstraZeneca ( AZN ) recently
announced that it has entered into an agreement with UK-based
company, Oxford Cancer Biomarkers Ltd. As per the terms of the
agreement, Oxford Cancer Biomarkers... Read >>
Spectrum Progresses with SPI-2012 - Analyst Blog
4/9/2013, 5:09 pm from Zacks.com in Investing, Business, Stocks
Spectrum Pharmaceuticals ( SPPI ) recently
initiated a phase II study on SPI-2012 (LAPS-GCSF). SPI-2012 is
being developed for the treatment of chemotherapy-induced
neutropenia which... Read >>
Illumina Introduces TruSight Tumor - Analyst Blog
4/8/2013, 6:10 pm from Zacks.com in Investing, Business, Stocks
Recently, Illumina Inc. ( ILMN ) expanded its
suite of TruSight content sets by adding TruSight Tumor to its
portfolio. TruSight's content set is created according to different
diseases.... Read >>
Balanced View on Gilead Sciences - Analyst Blog
3/28/2013, 6:26 pm from Zacks.com in Investing, Business, Stocks
On Mar 26, 2013, we reiterated our Neutral recommendation on
Gilead Sciences, Inc. ( GILD ) as we believe
that the stock is fairly priced at current levels with limited
scope for upside.... Read >>
More Protection for Biogen's Tecfidera - Analyst Blog
3/22/2013, 10:25 am from Zacks.com in Investing, Business, Stocks
Biogen Idec ( BIIB ) recently
announced additional patent protection for its oral multiple
sclerosis candidate, Tecfidera (dimethyl fumarate). The company
said that the US Patent and... Read >>
SGEN Seeks Adcetris Label Expansion - Analyst Blog
3/19/2013, 7:15 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics, Inc. ( SGEN ) recently
announced the submission of a supplemental biologics license
application (sBLA) to the US Food and Drug Administration (FDA) for
the use of Adcetris... Read >>
XOMA Posts Narrower Loss - Analyst Blog
3/14/2013, 1:16 pm from Zacks.com in Investing, Business, Stocks
XOMA Corporation ( XOMA ) reported
fourth-quarter 2012 loss of 15 cents per share, narrower than the
year-ago loss of 36 cents and the Zacks Consensus Estimate of a
loss of 24 cents. Lower... Read >>
Benzinga Market Primer: Tuesday, March 12
3/12/2013, 6:49 am from Benzinga in Investing, Bonds, Commodities, Economy, International
Futures Slide on Asian Weakness U.S. equity futures slid in early pre-market trade after Asian
shares reversed early gains to close lower. The Japanese Nikkei
Index broke an eight-day winning... Read >>
XOMA's Gevokizumab Study Update - Analyst Blog
1/14/2013, 5:11 pm from Zacks.com in Investing, Business, Stocks
XOMA Corporation ( XOMA ) recently
announced interim data from a phase II proof-of-concept (POC) study
on gevokizumab, which is being developed for the treatment of
inflammatory facial... Read >>
XOMA Provides Update on Gevokizumab - Analyst Blog
1/2/2013, 2:45 pm from Zacks.com in Investing, Business, Stocks
XOMA Corporation ( XOMA )
recently announced that it intends to include active non-infectious
anterior scleritis in the gevokizumab proof-of-concept program.
Non-infectious anterior... Read >>